Adjuvant therapy for cutaneous malignant melanoma - 11/09/11
Doi : 10.1016/S0190-9622(97)80329-5
Marie-France Demierre, MD, FRCPC *, Howard K. Koh, MD, MPH ⁎
Departments of Dermatology, Medicine, Epidemiology, and Biostatistics, Boston University Schools of Medicine and Public Health, and the Skin Oncology Program, Boston Medical Center, Boston, Massachusetts, USA
**Reprint requests: Howard K. Koh, MD, MPH, FACP, Professor of Dermatology, Medicine and Public Health, Boston University Medical Center, 720 Harrison Ave., D.O.B. 801A, Boston, MA 02118-2334.
Abstract |
We discuss the current status of adjuvant therapy for melanoma by first reviewing the rationale and goals of adjuvant therapy and then analyzing the results of published randomized trials. We pay particular attention to adjuvant interferon trials that raise many challenging issues in the management of patients with melanoma at high risk of recurrence. Past adjuvant trials have used immunotherapeutic approaches, chemotherapy, radiation therapy, as well as hormonal and retinoid therapy. We also summarize ongoing adjuvant trials.
Le texte complet de cet article est disponible en PDF.© 1997
Publié par Elsevier Masson SAS.
Vol 36 - N° 5
P. 747-764 - mai 1997 Retour au numéro
Article précédent
- Long-term follow-up of cryosurgery of basal cell carcinoma of the eyelid
- Gun Lindgren, Olle Larkö
- Is it lymphoma or lymphomatoid papulosis?
- Marie-France Demierre, Lynne J. Goldberg, Marshall E. Kadin, Howard K. Koh
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?